Most Read Articles
4 days ago
No association exists between physical activity and the risk of urological cancer, according to a population-based prospective study in Japan.
5 days ago
Patients with childhood-onset inflammatory bowel disease are more likely to die than the general population, a study suggests.
5 days ago
Reduced caloric intake results in a significant improvement in glucose metabolism and body-fat composition, including liver-fat content, according to a study. Changes in ferritin levels appear to mediate the striking reduction in liver fat.
Pearl Toh, 5 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.

Regorafenib the drug of choice second-line HCC treatment

10 Jan 2019

Regorafenib may be used as the agent of choice in the second-line treatment of hepatocellular carcinoma (HCC) in sorafenib-intolerant patients, with cabozantinib as a possible alternative, according to a network meta-analysis.

Researchers performed a systematic review of randomized controlled trials evaluating different drugs for the second-line treatment of advanced HCC. Overall survival (OS) was the primary study endpoint, with everolimus selected as the common comparator for efficacy analyses and placebo for safety analyses.

Subgroup analyses estimated OS according to Asian ethnicity, presence of hepatitis B or hepatitis C infection, macrovascular invasion, and extrahepatic metastases. Other outcome variables included progression-free survival (PFS), rates of grade 3–5 adverse events and treatment discontinuation due to adverse events.

The meta-analysis included 13 RCTs, yielding a total of 5,076 patients and evaluating 11 drugs. Pooled data revealed that OS was significantly longer with regorafenib (hazard ratio [HR], 0.60; 95 percent CI, 0.44–0.81) and with cabozantinib (HR, 0.72; 0.55–0.95) than with everolimus. The positive effect of regorafenib on OS tended to persist across patient subgroups.

Regorafenib also significantly prolonged PFS (HR, 0.46; 0.35–0.62) but substantially increased the rates of grade 3–5 adverse events (odds ratio [OR], 3.18; 2.22–4.54) and treatment discontinuation due to adverse events (odds ratio, 2.67; 1.21–5.87).

Advanced HCC accounts for the second leading cause of cancer-related deaths, with either sorafenib or lenvatinib used in the first-line setting, researchers noted. The findings suggest that regorafenib may be better than cabozantinib in the second-line treatment of HCC in patients who cannot tolerate their previous medication.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
No association exists between physical activity and the risk of urological cancer, according to a population-based prospective study in Japan.
5 days ago
Patients with childhood-onset inflammatory bowel disease are more likely to die than the general population, a study suggests.
5 days ago
Reduced caloric intake results in a significant improvement in glucose metabolism and body-fat composition, including liver-fat content, according to a study. Changes in ferritin levels appear to mediate the striking reduction in liver fat.
Pearl Toh, 5 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.